Why did GAAP earnings fall so sharply in Q4 2019?

Q4 GAAP EPS of $1.66 was reduced by $0.49 per share of charges not included in prior guidance: a $134 million pre-tax restructuring charge ($0.20) tied to the new operating model and a $214 million pre-tax significant litigation charge ($0.29) related to PFAS matters. Excluding the litigation charge, adjusted Q4 EPS was $1.95, down about 16% from $2.31 in Q4 2018.

Is 3M's underlying business growing?

Not on an organic basis. Q4 organic local-currency sales declined 2.6% and full-year organic sales declined 1.5%. Reported growth in Q4 was driven by acquisitions, mainly the Health Care business, which grew 25.4% in U.S. dollars. Transportation and Electronics (down 5.9% organically) and Safety and Industrial (down 2.8%) remained weak.

How strong is 3M's cash flow and what is its impact on leverage?

Free cash flow was a record $5.4 billion in 2019, but 3M's net debt rose to $17.8 billion from $11.4 billion as it funded roughly $5.0 billion in acquisitions and $3.3 billion in dividends. Management's 2020 guidance of 95% to 105% free cash flow conversion suggests cash generation remains a key support for the dividend and debt reduction.

What does the 2020 outlook imply for investors?

The guidance calls for 2020 EPS of $9.30 to $9.75 versus adjusted 2019 EPS of $9.10, implying modest growth. Organic local-currency growth is expected to be flat to 2%, and ROIC of 18% to 21% is below 2019's 17.5% only at the low end, meaning returns would need to improve materially in the upper range. Achieving the outlook depends on a return to organic growth in weak end markets.

What is the status of the PFAS litigation exposure?

3M updated its PFAS litigation assessment in Q4 2019, citing productive settlement discussions with multiple parties. It also expanded its evaluation of environmental matters at historical manufacturing sites and other locations that may have used or disposed of PFAS-containing materials. The company recorded a $214 million charge in Q4 and $762 million for the full year, including coal mine dust respirator litigation. The filing does not quantify remaining exposure, so the scale of future charges remains uncertain.

MMM 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed January 28, 2020. Cited figures are marked; the original filing is the authoritative source.

3M reported fourth-quarter and full-year 2019 results on January 28, 2020, and paired them with a restructuring and a new global operating model.

Q4 sales rose 2.1% to $8.1 billion^a, but organic local-currency sales fell 2.6%, and acquisitions (chiefly the Health Care deal) drove the reported growth. GAAP EPS of $1.66 was down 27% and included $0.49 per share of charges: a $0.20 restructuring charge tied to roughly 1,500 position cuts and a $0.29 significant litigation charge, mostly related to PFAS matters. Adjusted Q4 EPS, excluding the litigation charge, was $1.95, down about 16% from the adjusted $2.31 a year earlier.

Full-year sales declined 1.9% to $32.1 billion^b, with organic local-currency sales down 1.5%. Full-year GAAP EPS was $7.81 and adjusted EPS was $9.10, down 13%. Cash generation was the bright spot.

Full-year operating cash flow was $7.1 billion^c and free cash flow reached a record $5.4 billion, with 118% conversion of net income. Q4 free cash flow conversion was 186%. However, free cash flow was helped by the non-recurring charges, and net debt rose to $17.8 billion from $11.4 billion as 3M spent about $5.0 billion on acquisitions, primarily Acelity/KCI in Health Care, while also paying $3.3 billion in dividends.

Total debt rose to $20.3 billion^d. For 2020, 3M guided to EPS of $9.30 to $9.75, organic local-currency growth of flat to 2%, free cash flow conversion of 95% to 105%, and ROIC of 18% to 21%.

The guidance implies modest earnings growth over the 2019 adjusted base, with the operating model change and about $40 to $50 million of 2020 savings intended to support it. Investors will likely focus on whether organic growth returns, the scale and trajectory of PFAS litigation exposure, and whether leverage stays manageable given the elevated debt load.

02—Key points

Key Highlights

Q4 2019 sales of $8.1B rose 2.1% reported, but organic local-currency sales fell 2.6%; acquisitions contributed 5.6 points
Q4 GAAP EPS of $1.66 (down 27%) included $0.49 of non-recurring charges: $0.20 restructuring and $0.29 litigation; adjusted Q4 EPS was $1.95
FY2019 GAAP EPS of $7.81 and adjusted EPS of $9.10 (down 13%) on sales of $32.1B (down 1.9%)
Record FY2019 free cash flow of $5.4B (up 10%) with 118% conversion, supported by $7.1B operating cash flow
Restructuring to eliminate about 1,500 positions, with expected annual pre-tax savings of $110M to $120M ($40M to $50M in 2020)
Net debt rose to $17.8B from $11.4B after roughly $5.0B in acquisitions and $3.3B in dividends
2020 guidance: EPS of $9.30 to $9.75, organic growth of flat to 2%, free cash flow conversion of 95% to 105%, and ROIC of 18% to 21%

03—Questions

Frequently Asked Questions

Why did GAAP earnings fall so sharply in Q4 2019?
Q4 GAAP EPS of $1.66 was reduced by $0.49 per share of charges not included in prior guidance: a $134 million pre-tax restructuring charge ($0.20) tied to the new operating model and a $214 million pre-tax significant litigation charge ($0.29) related to PFAS matters. Excluding the litigation charge, adjusted Q4 EPS was $1.95, down about 16% from $2.31 in Q4 2018.
Is 3M's underlying business growing?
Not on an organic basis. Q4 organic local-currency sales declined 2.6% and full-year organic sales declined 1.5%. Reported growth in Q4 was driven by acquisitions, mainly the Health Care business, which grew 25.4% in U.S. dollars. Transportation and Electronics (down 5.9% organically) and Safety and Industrial (down 2.8%) remained weak.
How strong is 3M's cash flow and what is its impact on leverage?
Free cash flow was a record $5.4 billion in 2019, but 3M's net debt rose to $17.8 billion from $11.4 billion as it funded roughly $5.0 billion in acquisitions and $3.3 billion in dividends. Management's 2020 guidance of 95% to 105% free cash flow conversion suggests cash generation remains a key support for the dividend and debt reduction.
What does the 2020 outlook imply for investors?
The guidance calls for 2020 EPS of $9.30 to $9.75 versus adjusted 2019 EPS of $9.10, implying modest growth. Organic local-currency growth is expected to be flat to 2%, and ROIC of 18% to 21% is below 2019's 17.5% only at the low end, meaning returns would need to improve materially in the upper range. Achieving the outlook depends on a return to organic growth in weak end markets.
What is the status of the PFAS litigation exposure?
3M updated its PFAS litigation assessment in Q4 2019, citing productive settlement discussions with multiple parties. It also expanded its evaluation of environmental matters at historical manufacturing sites and other locations that may have used or disposed of PFAS-containing materials. The company recorded a $214 million charge in Q4 and $762 million for the full year, including coal mine dust respirator litigation. The filing does not quantify remaining exposure, so the scale of future charges remains uncertain.

04—Continue

← View all 8-K filings